This systematic review and meta-analysis aim to provide current evidence on the efficacy and safety of GLP-1 RAs as an anti-obesity treatment in obese or overweight non-diabetic pediatric and adolescent populations. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.